IntroductionPatients with kidney failure requiring hemodialysis are at high risk for hyperkalemia between treatments which is associated with increased cardiovascular morbidity and mortality. Early detection of hyperkalemic events may be useful to prevent adverse outcomes and their associated costs. We performed a cost-utility analysis comparing an intervention where a real-time potassium monitoring device is administered in hemodialysis patients in comparison to usual care. MethodsWe developed a cost-utility model with microsimulation from the perspective of the United States health care payer. Primary outcomes included the monthly cost-effectiveness threshold cost and break-even cost per patient attributable to the intervention and the incremental cost-effectiveness ratio comparing the intervention to usual care. A 25% reduction in hyperkalemic events was applied as a baseline device effectiveness estimate. Concurrent first and second order microsimulations were performed using 10%, 25%, and 50% effectiveness estimates as sensitivity analyses. Results are presented over a 10-year time horizon in 2022 United States Dollars (USD) and a willingness-to-pay threshold of $100,000 USD per quality-adjusted-life year (QALY) was considered. ResultsOver ten-years, threshold and break-even analysis yielded maximum monthly costs of $201.10 USD and $144.15 USD per patient respectively. The intervention was associated with reduced mean costs ($6,381.21 USD) and increased mean QALYs (0.03) per patient, therefore was considered dominant. In sensitivity analysis, the intervention was dominant in 99% of simulations performed at all effectiveness rates. ConclusionsImplementing a real-time potassium monitoring device in hemodialysis patients has the potential for cost savings and improved outcomes from the perspective of the Unites States health care payer.
Read full abstract